Browse Articles

Discover research articles across all indexed journals

Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates

Nature Communications Prakash Jadhav, Xueying Liang, Ahmadullah Ansari et al. Feb 13, 2025 DOI: 10.1038/s41467-025-56902-x

Exploring the underlying mechanisms of customers’ intention to adopt product recommendations from live streamers: A moderated mediation approach

PLoS ONE Liping Zhang, Xueping Wu Feb 13, 2025 DOI: 10.1371/journal.pone.0314682

Live streaming has emerged as one of the indispensable channels for product information dissemination. Product recommendations from live streamers play an increasingly important role in customers’ purchasing decisions. Our study aims to understand the mechanism behind individuals’ intention to adopt product recommendations in live streaming. To that end, we implemented a moderated mediation model to test the direct and indirect effects of perceived value on customers’ intention to adopt product recommendations from live streamers, the mediating role of perceived credibility in the relationship between perceived value and adoption intention, the moderating role of sense of telepresence in the link between perceived value and perceived credibility, and the moderating role of self-identification in the association between perceived credibility and adoption intention. Results show that perceived credibility plays a partial intermediary role in the link between perceived value and adoption intention, sense of telepresence can positively predict perceived credibility but cannot significantly moderate the relationship between perceived value and adoption intention, and self-identification can positively buffer the association between perceived credibility and adoption intention, but negatively moderate the relationship between perceived value and adoption intention. This study advances theoretical research on product recommendations in the live-streaming context and provides practical inspiration for live streamers and managers of social commerce companies.

QTLs unlock RBC storage hemolysis secrets

Blood Robert Sertori, Sant-Rayn Pasricha Feb 13, 2025 DOI: 10.1182/blood.2024027136

An optoelectrochemical synapse based on a single-component n-type mixed conductor

Nature Communications Yazhou Wang, Wentao Shan, Hanrui Li et al. Feb 13, 2025 DOI: 10.1038/s41467-025-56814-w

Understanding the aliya pulsed electric field dose-response relationship: Implications for ablation size, thermal load, and immune response in an orthotopic murine breast cancer model

PLoS ONE Ebtesam H. O. Nafie, Chiara Pastori, Rupsa Acharya et al. Feb 13, 2025 DOI: 10.1371/journal.pone.0318440

Aliya®Pulsed Electric Field (PEF) technology is an emerging strategy in the field of cancer treatment, offering a novel approach to ablation therapy that does not rely on thermal mechanisms. By employing a multi-stage experimental setup, including potato tuber, porcine liver, and murine breast cancer models, we explored the dose-response relationship on ablation and immune modulation by varying the pulse packets delivered from 20 to 100. The biologic response observed with 60 packets represented a minimum effective dose yielding reproducible ablation parameters, immune response, and efficacy which could be augmented with immune checkpoint blockade. This pre-clinical analysis provides a first step toward understanding the therapeutic index for PEF technology beyond ablation, a consideration that will require robust clinical validation in well-designed prospective studies.

High-risk MCL: recognition and treatment

Blood Preetesh Jain, Michael Wang Feb 13, 2025 DOI: 10.1182/blood.2023022354

Abstract Significant progress in determining the molecular origins and resistance mechanisms of mantle cell lymphoma (MCL) has improved our understanding of the disease’s clinical diversity. These factors greatly impact the prognosis of patients with MCL. Given the dynamic alterations in MCL clones and disease evolution, it is crucial to recognize high-risk prognostic factors at diagnosis and relapse. Clinical factors include a high MCL International Prognostic Index score with a high Ki-67 proliferation index, early disease progression within 24 months of first-line treatment, >3 previous lines of therapy at relapse, and an aggressive (blastoid or pleomorphic) histology. Molecular aberrations include dysregulated cyclin D1, an aberrant SOX11-CD70 axis, upregulated Musashi-2, MYC rearrangement, metabolic reprogramming, and epigenetic changes. Other factors that contribute to high-risk MCL include an immune-depleted microenvironment and clone adaptability with complex chromosomal anomalies and somatic mutations in TP53, NSD2, CCND1, CDKN2A, BIRC3, SP140, KMT2D, NFkBIE, SMARCA4, and NOTCH2. Ultra-high-risk MCL is indicated by the coexistence of multiple high-risk prognostic factors in the relapse setting and can portend very short progression-free survival. As MCL treatments advance toward cellular therapies, resistance to anti-CD19 chimeric antigen receptor T-cell therapy is also observed. These findings necessitate revisiting the prognostic impact of high-risk factors, current management strategies, new bi- and trispecific T-cell engagers, combination therapies, novel therapeutic targets, and next-generation clinical trials for patients with high-risk MCL. This article provides a comprehensive update on recognizing and managing high-risk MCL and encompass current practices and future directions.

MorPhiC Consortium: towards functional characterization of all human genes

Nature Mazhar Adli, Laralynne Przybyla, Tony Burdett et al. Feb 13, 2025 DOI: 10.1038/s41586-024-08243-w

Natural variation of indels in the CTB3 promoter confers cold tolerance in japonica rice

Nature Communications Jin Li, Haifeng Guo, Qijin Lou et al. Feb 13, 2025 DOI: 10.1038/s41467-025-56992-7

Sample Size Impact (SaSii): An R script for estimating optimal sample sizes in population genetics and population genomics studies

PLoS ONE Matheus Scaketti, Patricia Sanae Sujii, Alessandro Alves-Pereira et al. Feb 13, 2025 DOI: 10.1371/journal.pone.0316634

Obtaining large sample sizes for genetic studies can be challenging, time-consuming, and expensive, and small sample sizes may generate biased or imprecise results. Many studies have suggested the minimum sample size necessary to obtain robust and reliable results, but it is not possible to define one ideal minimum sample size that fits all studies. Here, we present SaSii (Sample Size Impact), an R script to help researchers define the minimum sample size. Based on empirical and simulated data analysis using SaSii , we present patterns and suggest minimum sample sizes for experiment design. The patterns were obtained by analyzing previously published genotype datasets with SaSii and can be used as a starting point for the sample design of population genetics and genomic studies. Our results showed that it is possible to estimate an adequate sample size that accurately represents the real population without requiring the scientist to write any program code, extract and sequence samples, or use population genetics programs, thus simplifying the process. We also confirmed that the minimum sample sizes for SNP (single-nucleotide polymorphism) analysis are usually smaller than for SSR (simple sequence repeat) analysis and discussed other patterns observed from empirical plant and animal datasets.

Treatment of relapsed/refractory MCL

Blood Elisabeth Silkenstedt, Martin Dreyling Feb 13, 2025 DOI: 10.1182/blood.2023022353

Abstract Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma that is clinically characterized by its heterogeneous behavior, with courses ranging from indolent to highly aggressive cases with limited prognosis. Targeted treatment alternatives in first-line and relapse settings are more and more shaping the therapeutic landscape of MCL. The development and implementation of new targeted and immunotherapeutic approaches have already improved outcomes for patients with MCL with refractory or relapsed disease. However, long-term prognosis is still limited, and patients with relapsed/refractory (R/R) disease, especially those failing Bruton tyrosine kinase (BTK) inhibitor treatment, usually have a dismal outcome. This review summarizes the current and emerging treatment options for R/R MCL, focusing on the implementation of combined targeted treatment strategies such as BTK inhibitors and BCL2 inhibitors, as well as immune-therapeutic approaches including chimeric antigen receptor T cells and bispecific antibodies.

Stressosome-independent but RsbT-dependent environmental stress sensing in Bacillus subtilis

Nature Communications Rabindra Khadka, Brannon Maravich, Natalie Demarest et al. Feb 13, 2025 DOI: 10.1038/s41467-025-56871-1

EEG theta and alpha oscillations during tactical decision-making: An examination of the neural efficiency hypothesis in volleyball

PLoS ONE Thomas Kanatschnig, Norbert Schrapf, Lisa Leitner et al. Feb 13, 2025 DOI: 10.1371/journal.pone.0318234

According to the neural efficiency hypothesis (NEH), individuals with higher expertise in a domain use their brain more efficiently when processing domain-specific tasks and show more efficient brain activity than individuals with lower expertise. In this study 64 participants with differing levels of volleyball expertise were recruited to investigate the NEH by means of a volleyball-specific tactical decision-making task. The participants, which were allocated to three different expertise groups (based on prior volleyball experience), saw videos of setting situations of real volleyball matches and were asked to predict the outcome of these situations. Behavioral performance and event-related de-/synchronization (ERD/S) in the EEG theta and alpha bands during the completion of the task, were examined. Our results show significantly higher prediction accuracy in relation to volleyball expertise. Significantly stronger theta synchronization, as well as alpha desynchronization were observed during the tactical prediction condition compared to a control condition. No significant group differences in theta or alpha ERD/S were observed. Descriptive examinations of theta and alpha ERD/S distributions, which revealed mixed results regarding support for the NEH, are discussed. Our findings provide new insights to the ongoing debate on how the NEH applies to the domain of sport.

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Blood Viral Shah, George Giotopoulos, Hikari Osaki et al. Feb 13, 2025 DOI: 10.1182/blood.2022019306

Abstract Initial clinical trials with drugs targeting epigenetic modulators, such as bromodomain and extraterminal protein (BET) inhibitors, demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves an increased transcriptional plasticity within AML, which allows the cells to escape therapeutic pressure. In this study, we investigated the immediate epigenetic and transcriptional responses after BET inhibition and demonstrated that BET inhibitor–mediated release of bromodomain-containing protein 4 from chromatin is accompanied by acute compensatory feedback that attenuates downregulation or even increases the expression of specific transcriptional modules. This adaptation is marked at key AML maintenance genes and is mediated by p300, suggesting a rational therapeutic opportunity to improve outcomes by combining BET and p300 inhibition. p300 activity is required during all steps of resistance adaptation; however, the specific transcriptional programs that p300 regulates to induce resistance to BET inhibition differ, in part, between AML subtypes. As a consequence, in some AMLs, the requirement for p300 is highest during the earlier stages of resistance to BET inhibition, when p300 regulates transitional transcriptional patterns that allow leukemia-homeostatic adjustments. In other AMLs, p300 shapes a linear resistance to BET inhibition and remains critical throughout all stages of the evolution of resistance. Altogether, our study elucidates the mechanisms that underlie an “acute” state of resistance to BET inhibition, achieved through p300 activity, and how these mechanisms remodel to mediate “chronic” resistance. Importantly, our data also suggest that sequential treatment with BET and p300 inhibition may prevent resistance development, thereby improving outcomes.

Coarse-graining network flow through statistical physics and machine learning

Nature Communications Zhang Zhang, Arsham Ghavasieh, Jiang Zhang et al. Feb 13, 2025 DOI: 10.1038/s41467-025-56034-2

Genetic diversity and population structure analysis of Forsythia ovata, a Korean endemic, based on genotyping-by-sequencing

PLoS ONE Yoo-Bin Lee, Soonku So, Yoo-Jung Park et al. Feb 13, 2025 DOI: 10.1371/journal.pone.0317278

The perennial shrub Forsythia ovata Nakai, native to the Korean Peninsula, has a highly restricted natural habitat, occurring only in a small area within the Baekdudaegan Mountain Range located in Gangwon-do Province. These characteristics give this species high conservation value, but there is a significant lack of genetic concerning about its populations for conservation purposes. In this study, we utilized genotyping-by-sequencing (GBS) to examine the genetic diversity and population structure of F. ovata. Our analysis including 5,017 single nucleotide polymorphisms (SNPs) from 72 individuals, representing nine distinct populations. The results revealed a mean expected heterozygosity (He) of 0.212, indicating a moderate level of genetic diversity within the species. Additionally, a relatively low levels of genetic differentiation (FST) and high gene flow (Nm) between populations were detected. The analysis of molecular variance (AMOVA) results indicated that most genetic variation occurred within individuals, accounting for 86.66% of the total variance. In contrast, only 6.90% and 6.44% of the molecular variance was attributed to differences among individuals and between populations, respectively. Considering the results of Bayesian structure analysis on the basis of ∆ K, principal coordinate analysis and phylogenetic analysis, we propose two management units for conservation. In addition, given the current conditions faced by F. ovata, both in situ and ex situ conservation should be considered for some populations (SG and BD).

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar et al. Feb 13, 2025 DOI: 10.1182/blood.2024025454

Abstract Mosunetuzumab, a CD20×CD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal phase 1/2 study after a median follow-up of 37.4 months in 90 patients with relapsed/refractory (R/R) follicular lymphoma (FL) and ≥2 prior lines of therapy treated with fixed-duration mosunetuzumab. Investigator-assessed complete response (CR) rate and objective response rate were 60.0% (95% confidence interval [CI], 49.1-70.2) and 77.8% (95% CI, 67.8-85.9), respectively. Among 70 responders, median duration of response was 35.9 months (95% CI, 20.7 to not estimable [NE]). Among 54 patients who achieved CR, 49 remained in CR at the end of treatment; median duration of CR was not reached (NR; 95% CI, 33.0 to NE); Kaplan-Meier-estimated 30-month remission rate was 72.4% (95% CI, 59.2-85.6). Estimated 36-month overall survival (OS) rate was 82.4% (95% CI, 73.8-91.0); median OS was NR (95% CI, NE to NE). Median progression-free survival was 24.0 months (95% CI, 12.0 to NE). Median time to CD19+ B-cell recovery was 18.4 months (95% CI, 12.8-25.0) after 8 cycles of mosunetuzumab treatment. No new cytokine release syndrome events or fatal, serious, or grade ≥3 adverse events were reported. With extended follow-up, mosunetuzumab demonstrated high response rates, durable remissions, and manageable safety with no long-term concerns. This supports outpatient mosunetuzumab administration as an off-the-shelf, fixed-duration, safe, and effective treatment for patients with R/R FL, including those with high-risk disease. This trial was registered at www.clinicaltrials.gov as #NCT02500407.

Solvent-free fabrication of ultrathin two-dimensional metal oxides/sulfides in a fixed interlayer by geometric confinement

Nature Communications Weixue Wang, Yang Liu, Xinjie Du et al. Feb 13, 2025 DOI: 10.1038/s41467-025-56912-9

Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review

PLoS ONE Nathan J. Creber, Jameel Muzaffar, Shravan Gowrishankar et al. Feb 13, 2025 DOI: 10.1371/journal.pone.0318165

Hearing loss is a significant health burden across all stages of life. One in 5 people suffer hearing loss, with 5% of the world’s population experiencing disabling hearing loss. A large proportion of this loss is the consequence of damage or loss of neurosensory structures, termed “sensorineural” hearing loss. A recent advance in the treatment of sensorineural hearing loss has occurred, with the advent of inner ear stem cell therapy. Focus has pivoted from augmenting existing neural structures to regenerating neural frameworks. To date, stem cell therapy is limited by the host immune system and rejection of donor cells. A better understanding of immunity in the inner is ear required to progress stem cell therapy for hearing loss. This review outlines a contemporary understanding of the inner ear immune system. We discuss concepts of immune dysregulation that may lead to common inner ear pathologies, and, in doing so, review the efficacy of current pharmacotherapies that mitigate end organ damage through a process of immunosuppression. Current literature is appraised through a systematic review exploring two areas of focus; immunosuppression therapies for the treatment of inner ear pathology associated immune dysregulation, and, subsequently, the efficacy of immunosuppressive agents in translational models of inner ear stem cell therapy. Through greater understanding of these concepts, and systematic appraisal of the literature, this review summarises the literature for contemporary immunosuppressive regimes that may facilitate stem cell accommodation in the cochlea and auditory nerve.

Novel CAR T cells to combat antigen escape in AML

Blood Nadia El Khawanky Feb 13, 2025 DOI: 10.1182/blood.2024027364

Author Correction: A multi-model study to inform the United States’ 2035 NDC

Nature Communications Gokul Iyer, Alicia Zhao, Adriana Bryant et al. Feb 13, 2025 DOI: 10.1038/s41467-025-56971-y